It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.

Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

RFK Jr.'s comments about the gene-editing technology raise a question about how he would regulate it as head of HHS.

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...

Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

Visualizing cells after editing specific genes can help scientists learn new details about the function of those genes. But ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...